Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study

Table 6

Differences in the incidence of AEs between the elder and younger patients.

Type of AEs	Age <65 years N = 101 (%)	Age ≥65 years N = 66 (%)
Total AEs	86 (85.15)	54 (81.82)	0.568
Serious AEs	26 (25.74)	15 (22.73)	0.658
irAEs	10 (9.90)	9 (13.64)	0.457